These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3185919)

  • 1. Spatial disorientation in Parkinson's disease: no effect of levodopa substitution therapy.
    Hovestadt A; De Jong GJ; Meerwaldt JD
    Neurology; 1988 Nov; 38(11):1802-3. PubMed ID: 3185919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial disorientation as an early symptom of Parkinson's disease.
    Hovestadt A; de Jong GJ; Meerwaldt JD
    Neurology; 1987 Mar; 37(3):485-7. PubMed ID: 3822144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa improves spatial contrast sensitivity in Parkinson's disease.
    Hutton JT; Morris JL; Elias JW
    Arch Neurol; 1993 Jul; 50(7):721-4. PubMed ID: 8323475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of levodopa therapy in Parkinson's disease. II. Measurement of behavioural changes.
    Radbill R; Rosenberg G; Schwartz A
    Can Med Assoc J; 1974 Dec; 111(11):1218-22. PubMed ID: 4434291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of Parkinson's disease without levodopa.
    Goetz CG; Tanner CM; Shannon KM
    Neurology; 1987 Apr; 37(4):695-8. PubMed ID: 3561783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors that influence the occurrence of response variations in Parkinson's disease.
    de Jong GJ; Meerwaldt JD; Schmitz PI
    Ann Neurol; 1987 Jul; 22(1):4-7. PubMed ID: 3631919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of levodopa on postural stability evaluated by wearable inertial measurement units for idiopathic and vascular Parkinson's disease.
    Gago MF; Fernandes V; Ferreira J; Silva H; Rodrigues ML; Rocha L; Bicho E; Sousa N
    Gait Posture; 2015 Feb; 41(2):459-64. PubMed ID: 25480163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term experience with selegiline and levodopa in Parkinson's disease.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
    Pillon B; Dubois B; Cusimano G; Bonnet AM; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):201-6. PubMed ID: 2703838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prosody and levodopa in Parkinson's disease.
    Azevedo LL; Reis CA; Souza IS; Cardoso FE
    Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does levodopa aggravate Parkinson's disease?
    Blin J; Bonnet AM; Agid Y
    Neurology; 1988 Sep; 38(9):1410-6. PubMed ID: 3412589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of somatosensory feedback control of the tongue in Parkinson's disease: effect of L-Dopa therapy.
    Sandyk R; Brennan MJ
    S Afr J Commun Disord; 1982; 29():49-54. PubMed ID: 7186204
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa.
    Robertson LT; Hammerstad JP
    J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):41-50. PubMed ID: 8558149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levodopa treatment on contrast sensitivity in Parkinson's disease.
    Bulens C; Meerwaldt JD; Van der Wildt GJ; Van Deursen JB
    Ann Neurol; 1987 Sep; 22(3):365-9. PubMed ID: 3674801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off and on state assessment of swallowing function in Parkinson's disease.
    Warnecke T; Hamacher C; Oelenberg S; Dziewas R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):1033-4. PubMed ID: 24997546
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.